Cristina Sánchez-Quesada1, Estefanía Toledo2, Guadalupe González-Mata3, Maria Isabel Ramos-Ballesta3, José Ignacio Peis4, Miguel Ángel Martínez-González5, Jordi Salas-Salvadó6, Dolores Corella7, Montserrat Fitó8, Dora Romaguera9, Jesús Vioque10, Ángel M Alonso-Gómez11, Julia Wärnberg12, J Alfredo Martínez13, Luís Serra-Majem14, Ramon Estruch15, Francisco J Tinahones16, José Lapetra17, Xavier Pintó18, Josep A Tur19, Antonio Garcia-Rios20, Naomi Cano-Ibáñez21, Pilar Matía-Martín22, Lidia Daimiel23, Rubén Sánchez-Rodríguez24, Josep Vidal25, Clotilde Vázquez26, Emilio Ros27, Pablo Hernández-Alonso28, Rocío Barragan29, Julia Muñoz-Martínez30, Meritxell López31, Sandra González-Palacios10, Jessica Vaquero-Luna32, Edelys Crespo-Oliva33, M Angeles Zulet34, Vanessa Díaz-González35, Rosa Casas15, José Carlos Fernandez-Garcia36, José Manuel Santos-Lozano17, Ana Galera18, Tomás Ripoll-Vera37, Pilar Buil-Cosiales38, Silvia Canudas39, Raul Martinez-Lacruz29, Karla-Alejandra Pérez-Vega30, Ángel Rios31, Rosario Lloret-Macián40, Anai Moreno-Rodriguez32, Miguel Ruiz-Canela2, Nancy Babio39, Maria Dolores Zomeño Fajardo41, José J Gaforio42. 1. Center for Advanced Studies in Olive Grove and Olive Oils, University of Jaen, Campus Las Lagunillas S/n, 23071, Jaén, Spain; Immunology Division, Department of Health Sciences, Faculty of Experimental Sciences, University of Jaén, Jaén, Spain; Agri-food Campus of International Excellence (ceiA3), Córdoba, Spain. 2. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, Pamplona, Spain. 3. Preventive Medicine and Public Health Division, Department of Health Sciences, Faculty of Experimental Sciences, University of Jaén, Jaén, Spain. 4. Centro de Salud Bulevar (Servicio Andaluz de Salud, SAS), Jaén, Spain. 5. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, Pamplona, Spain; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Universitat Rovira I Virgili, Departament de Bioquímica I Biotecnologia, Unitat de Nutrició, Reus, Spain; University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain. 7. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain. 8. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Unit of Cardiovascular Risk and Nutrition, Institut Hospital Del Mar de Investigaciones Médicas Municipal D'Investigació Médica (IMIM), Barcelona, Spain. 9. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. 10. CIBER Epidemiología y Salud Pública (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain; Miguel Hernandez University, ISABIAL-UMH, Alicante, Spain. 11. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain. 12. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Nursing, School of Health Sciences, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. 13. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain; Precision Nutrition and Cardiometabolic Health Program, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. 14. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas de Gran Canaria, Spain. 15. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Internal Medicine, Institut D'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain. 16. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Virgen de La Victoria Hospital, Department of Endocrinology, Instituto de Investigación Biomédica de Málaga (IBIMA), University of Málaga, Málaga, Spain. 17. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain. 18. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona Spain. 19. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, 07122, Palma de Mallorca, Spain. 20. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. 21. CIBER Epidemiología y Salud Pública (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. 22. Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 23. Precision Nutrition and Cardiometabolic Health Program, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. 24. Centro de Salud Siero-Sariego, Asturias, Spain. 25. CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Endocrinology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. 26. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Endocrinology and Nutrition, Hospital Fundación Jimenez Díaz. Instituto de Investigaciones Biomédicas IISFJD, University Autónoma, Madrid, Spain. 27. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Hospital Clínic, IDIBAPS, Barcelona, Spain. 28. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Universitat Rovira I Virgili, Departament de Bioquímica I Biotecnologia, Unitat de Nutrició, Reus, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain; Virgen de La Victoria Hospital, Department of Endocrinology, Instituto de Investigación Biomédica de Málaga (IBIMA), University of Málaga, Málaga, Spain. 29. Department of Preventive Medicine, University of Valencia, Valencia, Spain. 30. Unit of Cardiovascular Risk and Nutrition, Institut Hospital Del Mar de Investigaciones Médicas Municipal D'Investigació Médica (IMIM), Barcelona, Spain. 31. Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. 32. Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain. 33. Department of Nursing, School of Health Sciences, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. 34. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain. 35. Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas de Gran Canaria, Spain. 36. Virgen de La Victoria Hospital, Department of Endocrinology, Instituto de Investigación Biomédica de Málaga (IBIMA), University of Málaga, Málaga, Spain. 37. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, 07122, Palma de Mallorca, Spain; Department of Cardiology, Hospital Son Llàtzer, 07198, Palma de Mallorca, Spain. 38. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, Pamplona, Spain; Servicio Navarro de Salud, Pamplona, Spain. 39. Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y La Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Universitat Rovira I Virgili, Departament de Bioquímica I Biotecnologia, Unitat de Nutrició, Reus, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain. 40. Centro Salud Cabo Huertas, Alicante, Spain. 41. Unit of Cardiovascular Risk and Nutrition, Institut Hospital Del Mar de Investigaciones Médicas Municipal D'Investigació Médica (IMIM), Barcelona, Spain; Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain. 42. Center for Advanced Studies in Olive Grove and Olive Oils, University of Jaen, Campus Las Lagunillas S/n, 23071, Jaén, Spain; Immunology Division, Department of Health Sciences, Faculty of Experimental Sciences, University of Jaén, Jaén, Spain; Agri-food Campus of International Excellence (ceiA3), Córdoba, Spain; CIBER Epidemiología y Salud Pública (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: jgaforio@ujaen.es.
Abstract
BACKGROUND AND AIMS: The aim of this study was to ascertain the association between the consumption of different categories of edible olive oils (virgin olive oils and olive oil) and olive pomace oil and ankle-brachial pressure index (ABI) in participants in the PREDIMED-Plus study, a trial of lifestyle modification for weight and cardiovascular event reduction in individuals with overweight/obesity harboring the metabolic syndrome. METHODS: We performed a cross-sectional analysis of the PREDIMED-Plus trial. Consumption of any category of olive oil and olive pomace oil was assessed through a validated food-frequency questionnaire. Multivariable linear regression models were fitted to assess associations between olive oil consumption and ABI. Additionally, ABI ≤1 was considered as the outcome in logistic models with different categories of olive oil and olive pomace oil as exposure. RESULTS: Among 4330 participants, the highest quintile of total olive oil consumption (sum of all categories of olive oil and olive pomace oil) was associated with higher mean values of ABI (beta coefficient: 0.014, 95% confidence interval [CI]: 0.002, 0.027) (p for trend = 0.010). Logistic models comparing the consumption of different categories of olive oils, olive pomace oil and ABI ≤1 values revealed an inverse association between virgin olive oils consumption and the likelihood of a low ABI (odds ratio [OR] 0.73, 95% CI [0.56, 0.97]), while consumption of olive pomace oil was positively associated with a low ABI (OR 1.22 95% CI [1.00, 1.48]). CONCLUSIONS: In a Mediterranean population at high cardiovascular risk, total olive oil consumption was associated with a higher mean ABI. These results suggest that olive oil consumption may be beneficial for peripheral artery disease prevention, but longitudinal studies are needed.
BACKGROUND AND AIMS: The aim of this study was to ascertain the association between the consumption of different categories of edible olive oils (virgin olive oils and olive oil) and olivepomace oil and ankle-brachial pressure index (ABI) in participants in the PREDIMED-Plus study, a trial of lifestyle modification for weight and cardiovascular event reduction in individuals with overweight/obesity harboring the metabolic syndrome. METHODS: We performed a cross-sectional analysis of the PREDIMED-Plus trial. Consumption of any category of olive oil and olivepomace oil was assessed through a validated food-frequency questionnaire. Multivariable linear regression models were fitted to assess associations between olive oil consumption and ABI. Additionally, ABI ≤1 was considered as the outcome in logistic models with different categories of olive oil and olivepomace oil as exposure. RESULTS: Among 4330 participants, the highest quintile of total olive oil consumption (sum of all categories of olive oil and olivepomace oil) was associated with higher mean values of ABI (beta coefficient: 0.014, 95% confidence interval [CI]: 0.002, 0.027) (p for trend = 0.010). Logistic models comparing the consumption of different categories of olive oils, olivepomace oil and ABI ≤1 values revealed an inverse association between virgin olive oils consumption and the likelihood of a low ABI (odds ratio [OR] 0.73, 95% CI [0.56, 0.97]), while consumption of olivepomace oil was positively associated with a low ABI (OR 1.22 95% CI [1.00, 1.48]). CONCLUSIONS: In a Mediterranean population at high cardiovascular risk, total olive oil consumption was associated with a higher mean ABI. These results suggest that olive oil consumption may be beneficial for peripheral artery disease prevention, but longitudinal studies are needed.
Authors: María Gutierrez-Salcedo; Manuel Parras-Rosa; Francisco José Torres-Ruiz; Manuela Vega-Zamora Journal: Nutrients Date: 2021-01-29 Impact factor: 5.717